The HIRA's Central Review and Coordination Committee revealed specific reasons for not recognising benefit of JW Pharma's Hemlibra (Emicizumab).

The HIRA released a June review of the Review and Assessment Committee on its portal on Thursday. There are five cases of deliberation, including Hemlibra, Soliris, ventricular assistive therapy, Spinraza, and hematopoietic stem cell transplantation. In the case of Hemlibra, the HIRA unusually disclosed the results on the 8th due to controversy over the standards.

Based on the data submitted by the medical institution, the central group said that cases A, B, and C lacked objective data to prove that it was difficult to secure venous blood vessels